

**AMERICAN CANCER SOCIETY
REQUEST FOR APPLICATIONS
NOVEL IDEAS IN PROSTATE CANCER
CELL BIOLOGY**

The American Cancer Society has earmarked \$750,000 for this grant cycle for Novel Ideas in Prostate Cancer Cell Biology. Application is open to investigators at any stage of their careers.

The first deadline for these applications is **April 1, 1998**. Subsequent deadlines will be October 15, 1998, and on those same dates through 1999. The grants awarded in response to this RFA will be for three years, up to \$65,000 per year, including 25% indirect costs, and will not be renewable. Approximately four non-renewable grants will be awarded each grant cycle for three years. Please contact the grants administration or development office at your institution for a special RFA application form, or download from <http://www.cancer.org>.

Questions concerning this RFA should be directed to Dr. Peter Ove (404) 329-7552.

**AMERICAN CANCER SOCIETY
REQUEST FOR APPLICATIONS
HEALTH POLICY AND OUTCOMES
RESEARCH—PROSTATE CANCER**

The American Cancer Society is earmarking \$1.5 million for this grant cycle for Health Policy and Outcomes Research in Prostate Cancer. Application is open to independent investigators at any stage of their careers.

The next deadline is **April 1, 1998**. Subsequent deadlines will be October 15, 1998, and on those same dates through 1999. The grants will be for three years, up to \$250,000 per year, including 25% indirect costs, and will be renewable as long as this remains a targeted priority area. At least two grants will be awarded each grant cycle, contingent on the quality of the applications. Please contact the grants administration or development office at your institution for a special RFA application form, or download it from <http://www.cancer.org>.

Questions concerning this RFA should be directed to Dr. Ralph Vogler at (404) 329-7542 or Dr. Frank Baker at (404) 329-7795.

Visit the AACR Website!

<http://www.aacr.org>

Coming Soon:

Abstracts of AACR Journal Articles

1998 Proceedings of the AACR

Anticipated launch date: on or before March 15

Turn to our website to find:

- ☐ AACR scientific meeting schedule
- ☐ Tables of Contents of AACR journals
- ☐ Instructions for Authors
- ☐ Information about AACR Research Fellowships and Young Investigator Awards
- ☐ The latest AACR newsletter, and more!

AMERICAN ASSOCIATION FOR CANCER RESEARCH

CD MARKER ANTIBODIES for PARAFFIN SECTIONS

New from Novocastra

CD2 This glycoprotein is the T cell receptor antigen for CD58 (LFA-3) and sheep erythrocytes. NCL-CD2-271 monoclonal antibody can be used to *identify CD2 expression on T cells in peripheral lymphoid tissue, cortical thymocytes, and most malignant cells of T cell origin.*

CD9 Also known as motility related protein 1 (MRP-1), CD9 is found on various blood cells and certain cells in the peripheral nervous system. Monoclonal antibody NCL-CD9 can help *determine the presence of this antigen in frozen and paraffin-embedded normal and tumor tissues.*

CD10 Initially described as the common acute lymphocytic leukemia antigen (CALLA), CD10 is located on normal and neoplastic cells of lymphoid and non-lymphoid origin. Monoclonal antibody NCL-CD10-270 may help *identify CALLA positive cells in lymphoid progenitor cells, immature B cells within bone marrow, and germinal center B cells.*

CD22 (BL-CAM) The CD22 antigen is expressed early in differentiating B lymphocytes and abundantly on hairy cell leukemias. This antigen is not present on peripheral blood T cells, T cell leukemias, granulocytes or monocytes. The monoclonal antibody NCL-CD22-2 may be helpful in *typing mature leukemias* and is also suitable for use in ELISAs.

CD31 (PECAM-1) Recognized as a cell-cell adhesion molecule, CD31 is expressed on platelets, monocytes, granulocytes, B cells, a subset of leukocytes and endothelial cells. It appears to play a role in angiogenesis, wound healing, thrombosis, and cell stabilization. NCL-CD31-1A10 mouse monoclonal antibody may be used as *an effective marker of endothelial cells* on both frozen and paraffin-embedded tissue sections.

These products are for research use only.

Contact Vector Laboratories to receive the complete Novocastra Laboratories 1998 catalog, featuring over **400** monoclonal and polyclonal antibodies.



VECTOR LABORATORIES, INC.

30 Ingold Road, Burlingame, CA 94010

(650) 697-3600 Fax: (650) 697-0339 E-mail: vector@vectorlabs.com

VECTOR LABORATORIES, LTD.

16 Wulfric Square, Bretton,
Peterborough PE3 8RF U.K.

(01733) 265530 Fax: (01733) 263048

E-mail: vector@vectorlabs.co.uk

VECTOR LABORATORIES (CANADA) INC.

3390 South Service Road
Burlington, Ontario, L7N 3J5

(905) 681-0900 Fax: (905) 681-0166

E-mail: vectorca@netinc.ca



Annual Meeting of the Cell Proliferation Society - 1998

Baltimore, Maryland @ Cross Keys Hotel

March 19
Reception

Thursday, 19 March 1998
18:00 - Welcome Reception

March 20
08:00 Breakfast Buffet
12:00 Lunch
15:00 Coffee break
19:00 Dinner

Workshops

Models

Friday, 20 March 1998

08:45 - *Meeting Opens, Announcements*
Sandra Wolman, Uniformed Services University of the Health Sciences
09:00 - *Workshop I - Cyclins and Cell Cycle Proteins*
Frank Traganos, Cancer Research Institute
- *Workshop II - Cell Kinetics by FCM*
Nicholas Terry, M.D. Anderson

Session I - Cell Cycle Models

13:00 - *Complexity Theory*
Stuart A. Kauffman, Santa Fe Institute
13:40 - *Complexity and Applications to normal and neoplastic cell growth*
Harvey Priesler, Rush Presbyterian Hospital Cancer Center
14:20 - *The Continuum Model: On G1-events and G1-controls in mammalian cells*
Stephen Cooper, University of Michigan
15:15 - 18:00 - *Contributed papers*

March 21
08:00 Breakfast buffet
10:00 Award presentation
11:00 Coffee Break
12:00 Lunch
15:30 Coffee break
19:30 Dinner

Viruses

Cancer

Saturday, 21 March 1998

09:00 - Schiffer Memorial Lecture - *Human leukemia: from chromosomes to cytokines*
Peter Nowell, University of Pennsylvania

Session II - Viruses and the Cell Cycle

10:20 - *Cell cycle changes in permissive cells infected with SV40*
John M. Lehman, Albany Medical College
11:20 - *Oncogenic evolution of astrocytes expressing SV40 T antigen*
James W. Jacobberger, Case Western Reserve University

Session III - Oncogenesis and Cell Death

13:00 - *Evolutionary sequences and proliferation pathways in solid tumors*
T. Vincent Shankey, Loyola University
13:40 - *Integration of molecular and kinetic cell cycle models*
Stanley E. Shackney, Allegheny University Health Sciences
14:20 - *Contributed papers*
15:45 - *Contributed papers*
17:00 - *Posters - Wine and Cheese Reception*

March 22
07:00 Council Meeting
07:45 Breakfast buffet
08:00 Business meeting
12:00 Meeting closes

Cell Cycle

Sunday, 22 March 1998

Session IV - Cell Cycle, Differentiation, and Death

09:00 - *Cell Cycle and Differentiation G1 and G2 checkpoints*
Donald Coffey, Johns-Hopkins University
10:00 - *Retinoic acid differentiates HL60 cells through the MAP Kinase pathway*
Andrew Yen, Cornell University
11:00 - *Cell Cycle Modulation to Enhance Apoptosis*
Philip Grimley, Uniformed Services University of the Health Sciences

For registration, abstract submission, or more information see: <http://odin.mdacc.tmc.edu/cellpro/cell3/> or contact James W. Jacobberger (jwj@po.cwru.edu, or FAX: 216-368-1969).



14th Annual Meeting on Oncogenes: Oncogenes, Tumor Suppressors and Signal Transduction in Cancer and Development

June 24-27, 1998

The Salk Institute

Organizers: Ron DePinho, Dan Donoghue, Martine Roussel

The meeting is being held for the FIRST TIME on the west coast in beautiful La Jolla. Emphasis will be placed on the control of cellular proliferation and signaling by oncogenes, tumor suppressors, and cell-cycle regulators. Principal investigators, graduate students, and postdoctoral researchers are all encouraged to attend. The format will consist of oral and poster presentations with plenary talks by distinguished investigators. This meeting is an exciting forum for young investigators to present and discuss their research. Cosponsored by the Foundation for Advanced Cancer Studies, Inc. and by The Salk Institute for Biological Studies.

•Information for registration can be found at <http://www.salk.edu/meetings.html>

Registration:

\$650 US (includes housing and meals)

\$500 US (includes meals only)

\$250 US (special rate for predoctoral students, includes housing and meals)

\$100 US (no meals, no housing)

Abstract deadline is April 30, 1998

Application and abstract forms can be obtained from Sheila Moles, The Salk Institute 10010 N. Torrey Pines Rd. La Jolla, CA 92037 Tel (619)453-4100x1615, fax (619)546-0838, e-mail: moles@salk.edu



National Cancer Institute Division of Clinical Sciences

Patients Sought for Immunotoxin Studies

The National Cancer Institute (NCI) seeks patients for a new clinical study involving immunotoxin erb-38 — a novel agent in which the variable regions of a monoclonal antibody against HER-2/neu have been linked to a truncated bacterial toxin. The reagent has been bioengineered to recognize the gene product of HER-2/neu.

Patients with breast, stomach, lung, ovarian, or colon cancer whose tumors express HER-2/neu are potential candidates. NCI will provide eligible patients with treatment and travel to the Clinical Center in Bethesda, Maryland. **Please call the NCI Clinical Studies Support Center at 1-888-NCI-1937.**

MEDICAL OFFICER

The Investigational Drug Branch of the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis (DCTD), is seeking two physicians with experience in the conduct of clinical research and development of biological anti-cancer investigational agents for the position of Medical Officer, GS-15. Candidates are required to be board-certified or board-eligible in internal medicine and medical oncology. U.S. citizenship is required.

The Biologics Evaluation Section of the IDB, CTEP, DCTD is responsible for preclinical and clinical development of novel agents for the treatment of cancer including differentiation agents, tumor vaccines, cytokines, immunotoxins, monoclonal antibodies, anti-sense agents and gene therapies. The Medical Officer will be responsible for formulating and executing national development plans for new investigational agents sponsored by the DCTD. The candidate will also be involved in evaluating preclinical data and selecting new agents for clinical development by the Division. The position requires extensive interaction with basic scientists, the Developmental Therapeutics Program of DCTD, intramural and extramural clinical investigators, clinical cooperative groups, pharmaceutical companies, and the FDA. Opportunities for continued clinical activity and participation in clinical research are also encouraged on an individual basis in collaboration with the Intramural Division of Clinical Sciences.

Salary range for these positions ranges from \$77,798 to \$101,142 per annum. Candidates may be eligible for an added allowance of up to \$20,000 per annum. Announcement No. 98-2309, call (301) 402-2789 for information regarding application procedures, Fax ID: 1894. Send application to:

**NIH/NCI/HRMC Branch, Executive Plaza South, Suite 550
6120 Executive Blvd., MSC 7209, Rockville, MD 20852-7209
by the closing date of 4-24-98.**

For more information, contact Mario Sznol, M.D. or James Zwiebel, M.D.
at 301-496-8798.

NIH is an Equal Opportunity Employer

Massachusetts General Hospital Cancer Center

The Massachusetts General Hospital Cancer Center is recruiting an oncologist with expertise in clinical cancer genetics. This individual is anticipated to work with multidisciplinary teams in the identification, evaluation, and counseling of patients or families at risk for carrying mutations in cancer predisposition genes. In addition, the individual would be expected to design, implement and execute clinical trials focusing on either epidemiology, screening or prevention strategies for patients carrying cancer predisposition mutations. Expertise in the clinical management of patients with breast malignancy is particularly desirable although individuals with expertise in other oncologic malignancies such as endocrine tumors, ovarian or gastrointestinal malignancies, or melanoma are also encouraged to apply. The appointment will be at the Instructor/Assistant Professor level depending on the qualifications of the candidate. The Massachusetts General Hospital is an equal opportunity employer and women and minorities are particularly encouraged to apply. Interested applicants should forward their resume with a cover letter to Michael V. Seiden, M.D., Ph.D., Deputy Chief, Division of Hematology/Oncology, 100 Blossom Street, Cox 640, Boston, MA 02114.

TENURE LINE FACULTY MEMBER IN MEDICAL ONCOLOGY

STANFORD UNIVERSITY SCHOOL OF MEDICINE—We are searching for a physician scientist at the level of assistant or associate professor in the Division of Oncology, Department of Medicine. Candidates should have an MD or MD/PhD, be trained in the subspecialty of medical oncology and be accomplished in research. They should be prepared to establish an independent laboratory program in cancer research. Applicants with expertise in molecular and cell biology, immunology, or genetics and in the translation of scientific methods and discoveries to problems in clinical oncology are especially encouraged. Salary support, laboratory space and startup funds are available for this position. Successful candidates will have demonstrated their ability to obtain peer reviewed research funding. Participation in clinical care and in teaching will be expected. Stanford University is committed to increasing representation of women and members of minority groups on its faculty and particularly encourages applications from such candidates. Please send curriculum vitae, a statement of career plans, and three names of references to: Ronald Levy, MD, Chief, Division of Oncology, Stanford University School of Medicine, SUMC M211, Stanford, CA 94305-5306.

M.D. OR M.D./Ph.D. MOLECULAR BIOLOGIST (HEAD AND NECK CANCER)

CHAO FAMILY COMPREHENSIVE CANCER CENTER

and

THE DEPARTMENT OF OTOLARYNGOLOGY- HEAD & NECK SURGERY

UNIVERSITY OF CALIFORNIA, IRVINE

An immediate opening exists in the area of head and neck cancer research and clinical practice, at the University of California, Irvine. The Department of Otolaryngology-Head & Neck Surgery and the Chao Family Comprehensive Cancer Center are jointly seeking an individual who possesses both clinical and research skills. The position is FTE-supported and tenure-track.

The Chao Family Comprehensive Cancer Center is one of the nation's thirty one NCI designated comprehensive cancer centers. The Cancer Center is under the leadership of Frank Meyskens, M.D. Seven research programs and seven research Core resources support the activity of the Center.

The Department of Otolaryngology-Head & Neck Surgery has a highly successful head and neck cancer program in conjunction with the Cancer Center. The Department's Chairman, Roger L. Crumley, M.D., seeks to strengthen this program by recruiting an individual who possesses the M.D. degree, (or M.D./Ph.D.), experience in molecular biology techniques, skill in clinical care and teaching, and a strong research history and interest. The position is supported by the Department, the Cancer Center, and a University of California FTE.

Send Curriculum Vitae to:

Frank Meyskens, M.D.
Director, Chao Family Comprehensive Cancer Center
U.C. Irvine Medical Center
101 City Drive
Orange, CA 92868